A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer

Background: Identification of appropriate markers for predicting clinical benefit with erlotinib in non-small-cell lung cancer (NSCLC) may be able to guide patient selection for treatment. This open-label, multicentre, phase II trial aimed to identify genes with potential use as biomarkers for clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, E.-H., Ramlau, R., Pluzanska, A., Kuo, H.-P., Reck, M., Milanowski, J., Au, J. S.-K., Felip, E., Yang, P.-C., Damyanov, D., Orlov, S., Akimov, M., Delmar, P., Essioux, L., Hillenbach, C., Klughammer, B., McLoughlin, P., Baselga, J.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813308/
https://www.ncbi.nlm.nih.gov/pubmed/20110292
http://dx.doi.org/10.1093/annonc/mdp520

Ejemplares similares

Ejemplares similares